ArticleInfection control and hospital epidemiology2020
A potential protective role of losartan against coronavirus-induced lung damage.
Article in Infection control and hospital epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.Molecules (Basel, Switzerland) · 2020Pooled it
- Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.International journal of clinical practice · 2021Trial
- Does long COVID in people living with HIV resemble the functional phenotype of non-HIV individuals who had moderate or severe acute COVID-19? A retrospective cross-sectional study.Frontiers in medicine · 2025Article
- Harnessing immunity: Immunomodulatory therapies in COVID-19.World journal of virology · 2024Review
- The effects of antihypertensive medications on severity and outcomes of hypertensive patients with COVID-19.Journal of human hypertension · 2023Observational
- Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets.International journal of molecular sciences · 2023Article
- Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections.Molecular pharmaceutics · 2023Article
- Does Losartan reduce the severity of COVID-19 in hypertensive patients?BMC cardiovascular disorders · 2022Article
- Review
- Correlation of ACE2 with RAS components after Losartan treatment in light of COVID-19.Scientific reports · 2021Article
- Hypertension and its management in COVID-19 patients: The assorted view.International journal of cardiology. Cardiovascular risk and prevention · 2021Review
- A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.European journal of pharmacology · 2021Review
- Pharmacological treatments of COVID-19.Pharmacological reports : PR · 2020Review
- Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.Cellular signalling · 2020Review
- Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review.Biological procedures online · 2020Review
- Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.